Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years
This study characterized guaifenesin pharmacokinetics in children aged 2 to 17 years (n = 40) who received a single oral dose of guaifenesin (age‐based doses of 100‐400 mg) 2 hours after breakfast. Plasma samples were obtained before and for 8 hours after dosing and analyzed for guaifenesin using li...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066754/ https://www.ncbi.nlm.nih.gov/pubmed/26632082 http://dx.doi.org/10.1002/jcph.682 |
_version_ | 1782460541638279168 |
---|---|
author | Thompson, Gary A. Solomon, Gail Albrecht, Helmut H. Reitberg, Donald P. Guenin, Eric |
author_facet | Thompson, Gary A. Solomon, Gail Albrecht, Helmut H. Reitberg, Donald P. Guenin, Eric |
author_sort | Thompson, Gary A. |
collection | PubMed |
description | This study characterized guaifenesin pharmacokinetics in children aged 2 to 17 years (n = 40) who received a single oral dose of guaifenesin (age‐based doses of 100‐400 mg) 2 hours after breakfast. Plasma samples were obtained before and for 8 hours after dosing and analyzed for guaifenesin using liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were estimated using noncompartmental methods, relationships with age were assessed using linear regression, and dose proportionality was assessed on 95% confidence intervals. Based on the upper dose recommended in the monograph (for both children and adolescents), area under the curve from time zero to infinity and maximum plasma concentration both increased with age. However, when comparing the upper dose for children aged 2 to 11 years with the lower dose for adolescents aged 12 to 17 years, similar systemic exposure was observed. As expected due to increasing body size, oral clearance (CL(o)) and terminal volume of distribution (V(z)/F) increased with age. Due to a larger increase in V(z)/F than CL(o), an increase in terminal exponential half‐life was also observed. Allometric scaling indicated no maturation‐related changes in CL(o) and V(z)/F. |
format | Online Article Text |
id | pubmed-5066754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50667542016-11-01 Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years Thompson, Gary A. Solomon, Gail Albrecht, Helmut H. Reitberg, Donald P. Guenin, Eric J Clin Pharmacol Pediatric Pharmacology This study characterized guaifenesin pharmacokinetics in children aged 2 to 17 years (n = 40) who received a single oral dose of guaifenesin (age‐based doses of 100‐400 mg) 2 hours after breakfast. Plasma samples were obtained before and for 8 hours after dosing and analyzed for guaifenesin using liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were estimated using noncompartmental methods, relationships with age were assessed using linear regression, and dose proportionality was assessed on 95% confidence intervals. Based on the upper dose recommended in the monograph (for both children and adolescents), area under the curve from time zero to infinity and maximum plasma concentration both increased with age. However, when comparing the upper dose for children aged 2 to 11 years with the lower dose for adolescents aged 12 to 17 years, similar systemic exposure was observed. As expected due to increasing body size, oral clearance (CL(o)) and terminal volume of distribution (V(z)/F) increased with age. Due to a larger increase in V(z)/F than CL(o), an increase in terminal exponential half‐life was also observed. Allometric scaling indicated no maturation‐related changes in CL(o) and V(z)/F. John Wiley and Sons Inc. 2016-01-24 2016-07 /pmc/articles/PMC5066754/ /pubmed/26632082 http://dx.doi.org/10.1002/jcph.682 Text en © 2016, The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Pediatric Pharmacology Thompson, Gary A. Solomon, Gail Albrecht, Helmut H. Reitberg, Donald P. Guenin, Eric Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title | Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title_full | Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title_fullStr | Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title_full_unstemmed | Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title_short | Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years |
title_sort | guaifenesin pharmacokinetics following single‐dose oral administration in children aged 2 to 17 years |
topic | Pediatric Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066754/ https://www.ncbi.nlm.nih.gov/pubmed/26632082 http://dx.doi.org/10.1002/jcph.682 |
work_keys_str_mv | AT thompsongarya guaifenesinpharmacokineticsfollowingsingledoseoraladministrationinchildrenaged2to17years AT solomongail guaifenesinpharmacokineticsfollowingsingledoseoraladministrationinchildrenaged2to17years AT albrechthelmuth guaifenesinpharmacokineticsfollowingsingledoseoraladministrationinchildrenaged2to17years AT reitbergdonaldp guaifenesinpharmacokineticsfollowingsingledoseoraladministrationinchildrenaged2to17years AT guenineric guaifenesinpharmacokineticsfollowingsingledoseoraladministrationinchildrenaged2to17years |